From the FDA Drug Label
9.1 Controlled Substance Desvenlafaxine is not a controlled substance.
- Pristiq, which is another name for desvenlafaxine, is not a controlled substance 1.
From the Research
No, Pristiq (desvenlafaxine) is not a controlled substance. It is a prescription medication classified as a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used to treat major depressive disorder. Unlike controlled substances such as benzodiazepines or opioids, Pristiq has a low potential for abuse and dependence, which is why it is not regulated under the Controlled Substances Act. However, it still requires a prescription from a healthcare provider because it can cause side effects and withdrawal symptoms if stopped abruptly. Patients should not discontinue Pristiq without medical supervision, as a gradual tapering schedule is typically recommended to minimize withdrawal effects. The medication works by increasing the levels of serotonin and norepinephrine in the brain, which helps improve mood, energy levels, and overall sense of well-being in people with depression, as supported by studies such as 2. Key points to consider when prescribing Pristiq include:
- It is generally well-tolerated, with common side effects including nausea, insomnia, and dizziness, as reported in studies such as 3 and 4.
- The recommended dose is 50 mg per day, with no additional therapeutic benefits seen at higher doses, as noted in 5 and 6.
- Desvenlafaxine has a simple metabolism and a lower risk of drug-drug interactions compared to other SNRIs, making it a useful addition to the options available for the treatment of major depressive disorder, as discussed in 2 and 6.